Table 1.
Tumor factors of stage III IMA-LN (-) and stage III IMA-LN (+) patients
Factors
|
Group
|
IMA-LN (-)
n = 282
|
IMA-LN (+)
n= 10
|
P value
|
Age (years)
|
<66
|
141 (50%)
|
4 (40%)
|
0.75
|
|
≥66
|
141 (50%)
|
6 (60%)
|
|
Sex
|
Female
|
137 (49%)
|
5 (50%)
|
0.535
|
|
Male
|
145 (51%)
|
5 (50%)
|
|
Operation time (min)
|
<240
|
132 (47%)
|
4 (40%)
|
0.758
|
|
≥240
|
152 (53%)
|
6 (60%)
|
|
Bleeding (ml)
|
<45
|
148 (52%)
|
7 (70%)
|
1.000
|
|
≥45
|
134 (48%)
|
3 (30%)
|
|
Tumor location
|
Descending
|
9 (3%)
|
0 (0%)
|
0.142
|
|
Sigmoid
|
107 (38%)
|
7 (70%)
|
|
|
Rectum
|
166 (59%)
|
3 (30%)
|
|
T factor a, *
|
T1, 2
|
68 (24%)
|
0 (0%)
|
0.124
|
|
T3, 4
|
214 (76%)
|
10 (100%)
|
|
Number of lymph node metastasis *
|
<4
|
221 (78%)
|
3 (30%)
|
0.001
|
|
≥4
|
61 (22%)
|
7 (70%)
|
|
Histopathological type b, †
|
Poorly differentiated
|
23 (8%)
|
3 (30%)
|
0.049
|
|
Well differentiated
|
259 (92%)
|
7 (70%)
|
|
Tumor size (mm)
|
<45
|
162 (57%)
|
4 (40%)
|
0.203
|
|
≥45
|
110 (43%)
|
6 (60%)
|
|
Venous invasion †
|
Absent
|
127 (45%)
|
4 (40%)
|
1.000
|
|
Present
|
155 (55%)
|
6 (60%)
|
|
Lymphatic invasion †
|
Absent
|
108 (38%)
|
1 (10%)
|
0.096
|
|
Present
|
174 (62%)
|
9 (90%)
|
|
CA19-9 (U/ml)
|
<37
|
244 (87%)
|
7 (70%)
|
0.152
|
|
≥37
|
35 (12%)
|
3 (30%)
|
|
CEA (ng/ml)
|
<5
|
167 (59%)
|
5 (50%)
|
0.745
|
|
≥5
|
113 (40%)
|
5 (50%)
|
|
IMA-LN (-), the absence of the inferior mesenteric artery lymph node metastasis
IMA-LN (+), the presence of the inferior mesenteric artery lymph node metastasis
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen
a, Depth of invasion: T1, tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor invasion of the sub serosa or within adventitia; T4, tumor penetration of the serosa or tumor invasion of adjacent organs
b, Histological type: well differentiated, well or moderately differentiated adenocarcinoma; poorly differentiated, poorly differentiated adenocarcinoma, signet ring cell carcinoma or mucinous carcinoma
*, According to the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8, and the Union for International Cancer Control
†, According to 8th edition of the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma
Table 2.
Tumor factors of stage III IMA-LN (+) and stage IV LCRC patients
Factors
|
Group
|
IMA-LN (+)
n = 10
|
Stage IV
n = 111
|
P value
|
Age (years)
|
<66
|
4 (40%)
|
52 (47%)
|
0.751
|
|
≥66
|
6 (60%)
|
59 (53%)
|
|
Sex
|
Female
|
5 (50%)
|
49 (44%)
|
0.751
|
|
Male
|
5 (50%)
|
62 (56%)
|
|
Operation time (min)
|
<240
|
4 (40%)
|
51 (46%)
|
0.754
|
|
≥240
|
6 (60%)
|
60 (54%)
|
|
Bleeding (ml)
|
<45
|
7 (70%)
|
48 (43%)
|
0.747
|
|
≥45
|
3 (30%)
|
63 (57%)
|
|
Tumor location
|
Descending
|
0 (0%)
|
7 (6%)
|
0.154
|
|
Sigmoid
|
7 (70%)
|
40 (36%)
|
|
|
Rectum
|
3 (30%)
|
64 (58%)
|
|
T factor a, *
|
T1, 2
|
0 (0%)
|
3 (2%)
|
1.000
|
|
T3, 4
|
10 (100%)
|
108 (98%)
|
|
Number of lymph node metastasis *
|
<4
|
3 (30%)
|
63 (57%)
|
0.183
|
|
≥4
|
7 (70%)
|
48 (43%)
|
|
Histopathological type b, †
|
Poorly differentiated
|
3 (30%)
|
17 (15%)
|
0.366
|
|
Well differentiated
|
7 (70%)
|
94 (85%)
|
|
Tumor size (mm)
|
<45
|
4 (40%)
|
28 (25%)
|
0.453
|
|
≥45
|
6 (60%)
|
83 (75%)
|
|
Venous invasion †
|
Absent
|
4 (40%)
|
23 (21%)
|
0.228
|
|
Present
|
6 (60%)
|
88 (79%)
|
|
Lymphatic invasion †
|
Absent
|
1 (10%)
|
36 (32%)
|
0.280
|
|
Present
|
9 (90%)
|
75 (68%)
|
|
CA19-9 (U/ml)
|
<37
|
7 (70%)
|
60 (54%)
|
0.510
|
|
≥37
|
3 (30%)
|
50 (45%)
|
|
CEA (ng/ml)
|
<5
|
5 (50%)
|
25 (23%)
|
0.118
|
|
≥5
|
5 (50%)
|
85 (76%)
|
|
IMA-LN (+), the presence of the inferior mesenteric artery lymph node metastasis
LCRC, left-sided colorectal carcinoma
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen
a, Depth of invasion: T1, tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor invasion of the sub serosa or within adventitia; T4, tumor penetration of the serosa or tumor invasion of adjacent organs
b, Histological type: well differentiated, well or moderately differentiated adenocarcinoma; poorly differentiated, poorly differentiated adenocarcinoma, signet ring cell carcinoma or mucinous carcinoma
*, According to the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8, and the Union for International Cancer Control
†, According to 8th edition of the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma
Table 3
Tumor factors of stage III IMA-LN (+) and stage IV (LYM) LCRC patients
Factors
|
Group
|
IMA-LN (+)
n= 10
|
Stage IV (LYM)
n = 12
|
P value
|
Age (years)
|
<66
|
4 (40%)
|
8 (67%)
|
0.391
|
|
≥66
|
6 (60%)
|
4 (33%)
|
|
Sex
|
Female
|
5 (50%)
|
6 (50%)
|
1.000
|
|
Male
|
5 (50%)
|
6 (50%)
|
|
Operation time (min)
|
<240
|
4 (40%)
|
3 (25%)
|
0.652
|
|
≥240
|
6 (60%)
|
9 (75%)
|
|
Bleeding (ml)
|
<45
|
7 (70%)
|
1 (8%)
|
0.055
|
|
≥45
|
3 (30%)
|
11 (92%)
|
|
Tumor location
|
Descending
|
0 (0%)
|
1 (8%)
|
0.198
|
|
Sigmoid
|
7 (70%)
|
4 (33%)
|
|
|
Rectum
|
3 (30%)
|
7 (59%)
|
|
T factor a, *
|
T1, 2
|
0 (0%)
|
0 (0%)
|
NA
|
|
T3, 4
|
10 (100%)
|
12 (100%)
|
|
Number of lymph node metastasis *
|
<4
|
3 (30%)
|
3 (25%)
|
1.000
|
|
≥4
|
7 (70%)
|
9 (75%)
|
|
Histopathological type b, †
|
Poorly differentiated
|
3 (30%)
|
6 (50%)
|
0.415
|
|
Well differentiated
|
7 (70%)
|
6 (50%)
|
|
Tumor size (mm)
|
<45
|
4 (40%)
|
3 (25%)
|
0.652
|
|
≥45
|
6 (60%)
|
9 (75%)
|
|
Venous invasion †
|
Absent
|
4 (40%)
|
3 (25%)
|
0.652
|
|
Present
|
6 (60%)
|
9 (75%)
|
|
Lymphatic invasion †
|
Absent
|
1 (10%)
|
2 (17%)
|
1.000
|
|
Present
|
9 (90%)
|
10 (83%)
|
|
CA19-9 (U/ml)
|
<37
|
7 (70%)
|
7 (58%)
|
0.675
|
|
≥37
|
3 (30%)
|
5 (42%)
|
|
CEA (ng/ml)
|
<5
|
5 (50%)
|
2 (17%)
|
0.172
|
|
≥5
|
5 (50%)
|
10 (83%)
|
|
IMA-LN (+), the presence of the inferior mesenteric artery lymph node metastasis
Stage IV (LYM), stage IV only with distant lymph node metastasis
LCRC, left-sided colorectal carcinoma
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen
a, Depth of invasion: T1, tumor invasion of the lamina propria or submucosa; T2, tumor invasion of the muscularis propria; T3, tumor invasion of the sub serosa or within adventitia; T4, tumor penetration of the serosa or tumor invasion of adjacent organs
b, Histological type: well differentiated, well or moderately differentiated adenocarcinoma; poorly differentiated, poorly differentiated adenocarcinoma, signet ring cell carcinoma or mucinous carcinoma
*, According to the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8, and the Union for International Cancer Control
†, According to 8th edition of the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma